Blood Test Determines Reduced and Oxidized Glutathione
|
By LabMedica International staff writers Posted on 31 Jul 2013 |

Image: API 3000 triple-quadrupole mass spectrometer (Photo courtesy of Applied Biosystems).
Diminished levels of glutathione (γ-glutamylcysteinylglycine, GSH) and the ratio of GSH to glutathione disulfide (GSSG) can serve as important indicators of oxidative stress and disease risk.
A simple and sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for measuring whole blood GSH and GSSG has been developed and can easily be implemented in clinical laboratories.
Scientists at Stanford University School of Medicine (CA, USA) developed an approach that minimizes preanalytical variability through a one-step procedure of deproteinization and derivatization that prevents artifactual oxidation of GSH, and is easily adapted to the clinical setting without requiring excessive constraints on sample handling or storage. The team used anonymous, residual blood samples from 59 healthy individuals, 31 males, and 28 females, with an age range 1 to 87 years, with a mean of 25 years.
Compounds were separated by liquid chromatography using a Hypercarb column (Thermo Scientific; Waltham, MA, USA) at room temperature. The GSH and GSSG ions and fragments were detected using the API 3000 triple-quadrupole mass spectrometer (Perkin-Elmer; Waltham, MA, USA). The final concentrations of GSH and GSSG were expressed in units of μmol/L of whole blood.
The lower limits of detection (LLOD) were 0.4 μM for GSH and 0.1 μM for GSSG and the lower limits of quantitation (LLOQ) were 1.5 μM for GSH and 0.1 μM for GSSG. There was excellent linearity for both GSH and GSSG over the ranges of physiologic normal, with inter- and intra-assay coefficient of variation of 3.1% to 4.3% and accuracy between 95% and 101%. Derivatized samples are stable for at least three years when stored at -80 °C and underivatized samples for at least 24 hours at either 4 °C or room temperature. As a group, the mean concentration ± standard deviation for GSH was 900 ± 140 μM, GSSG 1.17 ± 0.43 μM, and GSH/GSSG ratio was 880 ± 370.
The authors concluded that their LC–MS/MS method minimizes preanalytic variability through a one-step procedure of deproteinization and derivatization, and chromatographic conditions that eliminate ion suppression and increase precision and sensitivity. Additional advantages included the small sample requirement, simple and rapid preanalytical processing, and wide automation possibilities, which makes this method ideal for routine and large-scale clinical testing. The study was published on June 15, 2013, in the Journal of Chromatography B.
Related Links:
Stanford University School of Medicine
Thermo Scientific
Perkin-Elmer
A simple and sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for measuring whole blood GSH and GSSG has been developed and can easily be implemented in clinical laboratories.
Scientists at Stanford University School of Medicine (CA, USA) developed an approach that minimizes preanalytical variability through a one-step procedure of deproteinization and derivatization that prevents artifactual oxidation of GSH, and is easily adapted to the clinical setting without requiring excessive constraints on sample handling or storage. The team used anonymous, residual blood samples from 59 healthy individuals, 31 males, and 28 females, with an age range 1 to 87 years, with a mean of 25 years.
Compounds were separated by liquid chromatography using a Hypercarb column (Thermo Scientific; Waltham, MA, USA) at room temperature. The GSH and GSSG ions and fragments were detected using the API 3000 triple-quadrupole mass spectrometer (Perkin-Elmer; Waltham, MA, USA). The final concentrations of GSH and GSSG were expressed in units of μmol/L of whole blood.
The lower limits of detection (LLOD) were 0.4 μM for GSH and 0.1 μM for GSSG and the lower limits of quantitation (LLOQ) were 1.5 μM for GSH and 0.1 μM for GSSG. There was excellent linearity for both GSH and GSSG over the ranges of physiologic normal, with inter- and intra-assay coefficient of variation of 3.1% to 4.3% and accuracy between 95% and 101%. Derivatized samples are stable for at least three years when stored at -80 °C and underivatized samples for at least 24 hours at either 4 °C or room temperature. As a group, the mean concentration ± standard deviation for GSH was 900 ± 140 μM, GSSG 1.17 ± 0.43 μM, and GSH/GSSG ratio was 880 ± 370.
The authors concluded that their LC–MS/MS method minimizes preanalytic variability through a one-step procedure of deproteinization and derivatization, and chromatographic conditions that eliminate ion suppression and increase precision and sensitivity. Additional advantages included the small sample requirement, simple and rapid preanalytical processing, and wide automation possibilities, which makes this method ideal for routine and large-scale clinical testing. The study was published on June 15, 2013, in the Journal of Chromatography B.
Related Links:
Stanford University School of Medicine
Thermo Scientific
Perkin-Elmer
Latest Clinical Chem. News
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
- Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
Channels
Molecular Diagnostics
view channel
FDA Approves Expanded Liquid Biopsy Panel for Advanced Cancer Profiling
Timely, comprehensive tumor profiling helps clinicians make treatment selection decisions for patients with advanced cancer. Blood-based approaches can provide actionable insights from a simple draw and... Read more
Microbial Saliva Test Could Help Triage Esophageal Cancer Risk
Esophageal squamous cell carcinoma (ESCC) is highly lethal, partly because many patients are diagnosed only after swallowing becomes difficult and treatment options are largely palliative.... Read more
Expanded DPYD Genotyping Test Supports Safer Chemotherapy Dosing
Fluoropyrimidines such as 5-fluorouracil (5-FU) are chemotherapy drugs prescribed to more than two million cancer patients each year, but 10–20% of patients can experience severe, and sometimes fatal,... Read more
Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer
High-risk non–muscle-invasive bladder cancer frequently recurs after therapy, with about 30% of patients relapsing and roughly 10% dying within two years despite tumor resection, surveillance, and Bacillus... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read moreMicrobiology
view channel
New AMR Assay Supports Rapid Infection Control Screening in Hospitals
As antimicrobial resistance spreads worldwide, healthcare-associated infections are placing a growing burden on hospitals, increasing the need for faster and broader diagnostic solutions.... Read more
Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
In eastern Democratic Republic of the Congo, communities are confronting a resurgence of Bundibugyo ebolavirus, a rarer species for which no vaccines or treatments have been approved. Ebola is a highly... Read more
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read moreIndustry
view channel
Strategic Collaboration Advances RNA Foundation Models for Precision Oncology
Bulk RNA sequencing is increasingly used to study tumor biology, but standard analyses often reduce results to gene-level summaries that miss important transcript variants and mutation patterns.... Read more








